Back to Research Hub
Apogee Therapeutics, Inc.
APGE
$134.85+0.06 (+0.04%)
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders.
StreetsValue research for Apogee Therapeutics, Inc. (APGE)
Members get the full report for Apogee Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.